Rusnano, US fund to invest $760 mln in pharma venture
Megan Davies, Reuters
Russian state technology firm Rusnano is teaming up with a U.S. venture fund to invest around $760 million in a number of U.S. healthcare and pharmaceuticals firms, establish a manufacturing facility in Russia and bring new drugs to the Russian market.
Domain partners with RusNano on $760M biotech investment plan
John Carroll, Fierce Biotech
The Russians are back. After capturing the attention of the nanobio crowd with a few hefty investments in the U.S., RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.
Rusnano Teams Up With U.S. Fund Domain to Invest in Life Science
Jason Corcoran, BLOOMBERG
Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.